Neopharm Ltd Stock Return On Equity
| 092730 Stock | KRW 12,000 90.00 0.74% |
NeoPharm LTD fundamentals help investors to digest information that contributes to NeoPharm's financial success or failures. It also enables traders to predict the movement of NeoPharm Stock. The fundamental analysis module provides a way to measure NeoPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeoPharm stock.
NeoPharm |
NeoPharm LTD Company Return On Equity Analysis
NeoPharm's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current NeoPharm Return On Equity | 13.82 |
Most of NeoPharm's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeoPharm LTD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, NeoPharm LTD has a Return On Equity of 13.8195. This is much higher than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The return on equity for all Republic of Korea stocks is notably lower than that of the firm.
NeoPharm Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeoPharm's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeoPharm could also be used in its relative valuation, which is a method of valuing NeoPharm by comparing valuation metrics of similar companies.NeoPharm is currently under evaluation in return on equity category among its peers.
NeoPharm Fundamentals
| Return On Equity | 13.82 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 153.58 B | |||
| Shares Outstanding | 7.99 M | |||
| Shares Owned By Insiders | 38.94 % | |||
| Shares Owned By Institutions | 17.81 % | |||
| Price To Earning | 42.54 X | |||
| Price To Sales | 1.56 X | |||
| Revenue | 87.93 B | |||
| Gross Profit | 58.64 B | |||
| EBITDA | 24.3 B | |||
| Net Income | 17.71 B | |||
| Cash And Equivalents | 7.05 B | |||
| Total Debt | 101.79 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 4.20 X | |||
| Book Value Per Share | 4,777 X | |||
| Cash Flow From Operations | 21.68 B | |||
| Earnings Per Share | 576.00 X | |||
| Target Price | 36000.0 | |||
| Number Of Employees | 106 | |||
| Beta | 1.11 | |||
| Market Capitalization | 156.02 B | |||
| Total Asset | 143.41 B | |||
| Retained Earnings | 19.71 B | |||
| Working Capital | 16.77 B | |||
| Current Asset | 22.83 B | |||
| Current Liabilities | 6.06 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 143.41 B |
About NeoPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeoPharm LTD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoPharm LTD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in NeoPharm Stock
NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.